Sub-Navigation

• Investor News
• Ad-hoc Publications
• Archive

Bayer Links

• Bayer Global
• Nachhaltigkeit
• Presse

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Investor News

Search

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR News via E-Mail, RSS Feed or SMS.

Wednesday March 10, 2010

MR contrast agents for diagnosis of breast cancer

Bayer starts Phase III study to evaluate efficacy and safety of Gadovist® in magnetic resonance mammography

Monday March 01, 2010

Approval process begins in April 2010:

Bayer MaterialScience planning new world-scale TDI plant at Dormagen site

EUR 150 million investment in the future / New production process was developed in Dormagen / Energy savings of up to 60 percent versus conventional plants

Friday February 26, 2010

Bayer modifies Board of Management compensation system

Reduction of short-term incentive and strengthening of long-term compensation component / Extended share retention period under long-term incentive program / Increased personal investment in Bayer stock / Adjustments effective January 1, 2010 / Compensation system to be submitted to Annual Stockholders' Meeting for approval

Friday February 26, 2010

2009: operationally one of the strongest years - optimism for the future

Bayer successful in a difficult environment

Group sales EUR 31,168 million (minus 5.3 percent) / EBITDA before special items EUR 6,472 million (minus 6.6 percent) / Net income EUR 1,359 million (minus 20.9 percent) / Net cash flow significantly improved to EUR 5,375 million (plus 49 percent) / Net financial debt reduced by EUR 4.5 billion to EUR 9.7 billion / Core earnings per share expected to improve by about 10 percent in 2010

Wednesday February 24, 2010

Bayer proposes dividend for 2009 of EUR 1.40 per share

Thursday February 18, 2010

VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular Edema

Statistically significant improvement in vision achieved over 24 weeks / Results to be presented at the Angiogenesis 2010 - Clinical Trials meeting in Miami, Florida on February 20, 2010

Monday January 25, 2010

Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII Following Interim Analysis

Study will not be able to meet primary endpoint / Bayer remains committed to developing its long-acting recombinant factor VIII compounds; alternative candidates in development